On Wednesday, 27th October 2021, the company ‘Novavax’ has announced the completion of the company’s regulatory submission to the Medicines and Healthcare products Regulatory Agency (MHRA) of the United Kingdom for the authority of the company’s novel corona virus vaccine known as NVX-CoV2373, and this has also been marking the very first submission of a covid-19 vaccine based on the protein in the United Kingdom.
Novavax has now partnered with the Serum Institute of India for the purpose of manufacturing the novel corona virus, and in the last month, the Novavax and Serum Institute has filed the regulatory submissions for the World Health Organization (WHO) for the emergency use listing of the company’s corona virus vaccine.
Rick Crowley, executive vice president and chief operations officer said, the submission of the data to the UK MHRA has been responsible for leveraging their manufacturing the partnership along with the Serum Institute of India, which has been largest supplier of the novel corona virus vaccine in the world.
Stanley C. Erck, president and chief executive officer of Novavax said, this submission has been responsible for bringing the company significantly closer for the purpose of delivering millions of the doses of the very first corona virus vaccine based on protein, which has been built on a proven, and well-understood covid-19 vaccine platform that has been demonstrated the high efficiency against multiple mutated strains of the corona virus.
Novavax has now also completed the submission of all the modules that have been required by the UK MHRA for the review of the regulatory of the vaccine, and this also been including the pre-clinical, chemistry, and clinical, along with the manufacturing and controls (CMC) data.